Vericel Corp (VCEL) stock analysis

P/E against its history

Not enough price and earnings history to compare.

P/E above the industry

Vericel's P/E of 100.8 is above the Drugs median of 25.1.

EV/EBITDA against its history

Needs positive EBITDA and price history.

P/B above the industry

Vericel's price-to-book of 7.92 is above the Drugs median of 2.29.

Trading above fair value

The share price of $59.45 is above our fair value estimate of $16.78.

Margin of safety under 20%

The price is 254% above fair value, so there is no margin of safety.

Revenue growing 10%+ a year

Revenue grew 18.9% a year over the last three fiscal years.

EPS growth over 3 years

Needs positive EPS three years ago and today.

Earnings growth accelerating

Net income grew 155% over the last twelve months, against a 5-year average of 42.0% a year.

Growing faster than the industry

Revenue grew 25.3% over the last twelve months; the Drugs median is 8.0%.

Guidance raised

Vericel raised its 2026 Total revenue outlook on Jul 30, 2026.

Gross margin improving

Gross margin was 74.5% over the last twelve months, against 73.8% a year earlier.

Return on equity under 15%

Return on equity was 9.4% over the last twelve months and averaged -1.3% over five years; we look for 15% on both.

Return on capital over 10%

Return on invested capital was 10.6%, above the 10% that usually covers the cost of capital.

Return on equity above the industry

Vericel's return on equity of 9.4% is above the Drugs median of -58.9%.

Earnings grew over 5 years

Net income grew 42.0% a year on average over the last five fiscal years.

Net margin above its 5-year average

Net margin was 10.3% over the last twelve months, against a 5-year average of -1.2%.

Net margin above the industry

Vericel's net margin of 10.3% is above the Drugs median of -53.0%.

No debt

Vericel has no borrowings on its latest balance sheet.

Debt not rising

With no debt today, leverage cannot have risen.

Debt covered by cash flow

There is no debt to cover.

Interest well covered

Operating income covers interest expense 42.0 times.

Short-term assets cover short-term debts

Current assets are 5.13 times current liabilities.

Low bankruptcy risk

The Altman Z-score is 14.07; above 3 is the safe zone and below 1.8 the distress zone.

No dividend

Vericel has not paid a dividend in the last twelve months.

Yield against Treasuries

No dividend.

Yield against the market

No dividend.

Dividend stability

No dividend.

Earnings cover

No dividend.

Cash-flow cover

No dividend.